Mineralys Therapeutics presented data showing lorundrostat significantly reduces biomarkers linked to heart failure risk in patients with uncontrolled hypertension. The drug modulates key biological pathways related to fibrosis and heart failure, supporting its potential as a treatment. Lorundrostat is currently under FDA review with a decision expected by December 2026. These findings come from Phase 3 and Phase 2b trials involving over 1,000 participants, highlighting its effectiveness and safety in lowering blood pressure and impacting heart failure risk factors.
On World Blood Donor Day, June 14, 2026, more than 100 organizations in the US united to thank the 8 million annual blood donors and encourage more eligible people to donate. Blood donations are critical as a transfusion is needed every two seconds i...
The Phase 3 SENTRY trial showed that combining selinexor (NEXPOVIO®) with ruxolitinib significantly improved spleen volume reduction by 49.8% at week 24 compared to 28% with ruxolitinib alone in myelofibrosis patients. This combination also showed a ...
The daily transaction fees on the XRP Ledger have dropped below $400, signaling a decrease in network activity. This decline raises concerns about the current usage and demand for the XRP network. Investors and users are watching closely to see if th...
XRP has stabilized above the key $1 support level after a sharp drop from $1.30, with selling pressure fading between $1.05 and $1.10. This suggests sellers are losing conviction, but it is not yet a bullish reversal. For a clear uptrend, XRP needs t...
Despite Bitcoin's recent pullbacks and dominance holding near 60%, there is no strong rotation into altcoins like XRP and Solana (SOL) yet, with their BTC ratios down significantly since late 2023. However, XRP and SOL continue to attract steady inst...
